Pacira BioSciences upgraded by Truist with a new price target
$PCRX
Biotechnology: Pharmaceutical Preparations
Health Care
Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $27.00 | Equal Weight | Barclays |
| 11/17/2025 | Buy | H.C. Wainwright | |
| 7/25/2025 | $30.00 | Hold → Buy | Truist |
| 1/30/2025 | $8.00 → $25.00 | Sell → Hold | Truist |
| 8/13/2024 | $30.00 → $8.00 | Buy → Sell | Truist |
| 8/12/2024 | $42.00 → $11.00 | Overweight → Neutral | Piper Sandler |
| 8/12/2024 | $45.00 → $10.00 | Overweight → Underweight | JP Morgan |
| 8/12/2024 | Outperform → Mkt Perform | Raymond James |
Barclays initiated coverage of Pacira BioSciences with a rating of Equal Weight and set a new price target of $27.00
H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy
Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
-- Issues Statement in Response to DOMA's Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC ("DOMA") has nominated three director candidates to stand for election to the Pacira Board of Directors (the "Board") at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). Pacira's Board issued the following statement: The Pacira Board of Directors and managemen
Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30%ii; The Company's Underperformance is Reflected in Consistently Missed Earnings, Continuous Lowering of Guidance, Which is Then Missed, and a Complete Lack of Combined Profitability in the Last Two Yearsiii; We believe the Stock Price Reflects the Market's Lack of Trust in Management and the Board of Director's Utter Failure of OversightDOMA Asserts Frank Lee Should be Replaced Immediately; the Board Should Name an Interim CEO and Conduct a Formal Sale Process of the Business DOMA's Three Highly Qualified Nominees Possess Vast Ex
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira's Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. One employee received stock options to purchase
DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
S-8 - Pacira BioSciences, Inc. (0001396814) (Filer)
10-K - Pacira BioSciences, Inc. (0001396814) (Filer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. "2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. "Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors," said Laura Brege, independent board chair of Pacira. "We believ
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-actin
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. "Despite its prevalence, there c
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)